The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol
Abstract
Purpose: This phase II noncomparative randomized trial was conducted to determine the optimal sequencing and integration of paclitaxel/carboplatin with standard daily thoracic radiation therapy (TRT), in patients with locally advanced unresected stage III non–small-cell lung cancer (NSCLC). Survival data were compared with historical standard sequential chemoradiotherapy data from the Radiation Therapy Oncology Group. Patients and Methods: Patients with unresected stages IIIA and IIIB NSCLC, with Karnofsky performance status ≥ 70% and weight loss ≤ 10%, received two cycles of induction paclitaxel (200 mg/m 2)/carboplatin (area under the plasma concentration time curve [AUC] = 6) followed by TRT 63.0 Gy (arm 1, sequential) or two cycles of induction paclitaxel (200 mg/m 2)/carboplatin (AUC = 6) followed by weekly paclitaxel (45 mg/m 2)/carboplatin (AUC = 2) with concurrent TRT 63.0 Gy (arm 2, induction/concurrent), or weekly paclitaxel (45 mg/m 2)/carboplatin (AUC = 2)/TRT (63.0 Gy) followed by two cycles of paclitaxel (200 mg/m 2)/carboplatin (AUC = 6; arm 3, concurrent/consolidation). Results: With a median follow-up time of 39.6 months, median overall survival was 13.0, 12.7, and 16.3 months for arms 1, 2, and 3, respectively. During induction chemotherapy, grade 3/4 granulocytopenia occurred in 32% and 38% of patients on study arms 1 and 2, respectively. The most common locoregional grade 3/4 toxicity during and after TRT was esophagitis, which was more pronounced with the administration of concurrent chemoradiotherapy on study arms 2 and 3 (19% and 28%, respectively). Conclusion: Concurrent weekly paclitaxel, carboplatin, and TRT followed by consolidation seems to be associated with the best outcome, although this schedule was associated with greater toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., Katagami, N., & Ariyoshi, Y. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2692 · Cited by 1,495
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., Kirkpatrick, A., Koolen, M., Maat, B., Nijs, A., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260805 · Cited by 1,277
Dillman, R. O., Seagren, S. L., Propert, K. J., Guerra, J., Eaton, W. L., Perry, M. C., Carey, R. W., Frei, E. F., & Green, M. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231403 · Cited by 1,153
Dillman, R. O., Herndon, J., Seagren, S. L., Eaton, W. L., & Green, M. R. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.17.1210 · Cited by 923
Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer
Sause, W., Kolesar, P., Taylor, S., Johnson, D., Livingston, R., Komaki, R., Emami, B., Curran, W., Byhardt, R., Dar, A. R., et al. (2000) · Chest · doi:10.1378/chest.117.2.358 · Cited by 627
Self-citationVokes, E. E., Herndon, J. E., Crawford, J., Leopold, K. A., Perry, M. C., Miller, A. A., & Green, M. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.054 · Cited by 370
Impact of tumor control on survival in carcinoma of the lung treated with irradiation
Perez, C. A., Bauer, M., Edelstein, S., Gillespie, B. W., & Birch, R. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90061-1 · Cited by 318
Cited by
Curran, W. J., Paulus, R., Langer, C. J., Komaki, R., Lee, J. S., Hauser, S., Movsas, B., Wasserman, T., Rosenthal, S. A., Gore, E., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr325 · Cited by 1,233
Self-citationEttinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Demmy, T. L., Ganti, A. K. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0056 · Cited by 730
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7840 · Cited by 491
Lung cancer: New biological insights and recent therapeutic advances
Ramalingam, S. S., Owonikoko, T. K., & Khuri, F. R. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20102 · Cited by 471
Treatment of Stage III Non-small Cell Lung Cancer
Ramnath, N., Dilling, T. J., Harris, L. J., Kim, A. W., Michaud, G. C., Balekian, A. A., Diekemper, R., Detterbeck, F. C., & Arenberg, D. A. (2013) · Chest · doi:10.1378/chest.12-2360 · Cited by 442
Metadata
- Authors
- Belani, C. P., Choy, H., Bonomi, P., Scott, C., Travis, P., Haluschak, J., & Curran, W. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-09-01
- Volume
- 23
- Issue
- 25
- Pages
- 5883-5891
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2136240226
- Cited by
- 424
- References
- 13
- FWCI
- 21.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol. https://app.cochat.ai/papers/10.1200/jco.2005.55.405
- The paper
- Belani, C. P., Choy, H., Bonomi, P., Scott, C., Travis, P., Haluschak, J., & Curran, W. J. (2005). Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.55.405
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.